-
Mashup Score: 0
Program: Oral and Poster Abstracts Type: Oral Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real World Data Hematology Disease Topics & Pathways: Research, adult, Biological therapies, Lymphomas, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, Clinical Research, Diseases, Therapies, real-world evidence, Lymphoid Malignancies, Study Population, Human Michael Roderick Cook, MD
Source: ash.confex.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 2Paper: Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy - 5 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 627. Aggressive Lymphomas: Clinical an d Epidemiological: Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Hematology Disease Topics & Pathways: Research, adult, elderly, non-Hodgkin lymphoma, Lymphomas, epidemiology, B Cell lymphoma, Clinical Research, Diseases, aggressive lymphoma, real-world evidence, Lymphoid Malignancies, Study Population, Human Steven M. Bair, MD 1, Mayur Narkhede, MD 2 *, Zachary AK Frosch, MD, MSHP 3,
Source: ash.confex.comCategories: General Medicine News, Hematologists1Tweet-
📌#ASH23 [Top 10 agressive B-cell NHL abstracts] Abstract 68 - Steven M. Bair et al. Treatment intensity and outcomes in elderly patients with DLBCL receiving 1st line therapy: RD R-CHOP vs. SD R-CHOP vs. non-anthracycline alternative regimens. 👉https://t.co/pRLKkj9mB4 https://t.co/R8hG30Y5EZ
-
-
Mashup Score: 4
Program: Oral and Poster Abstracts Type: Oral Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Improving CAR-T Therapies for B Cell Malignancies Hematology Disease Topics & Pathways: drug development, Therapies Pierre Sesques 1 *, Roch Houot, MD, PhD 2 *, Yassine Al Tabaa, MD, PhD, PharmD 3 *, Fabien Le Bras, MD 4 *, Loic Ysebaert, MD, PhD 5 *, Fabrice Jardin, MD PhD 6 *, Choquet Sylvain 7 *, Jacques-Olivier Bay, MD, PhD 8 *, Francois Xavier Gros, MD 9 *, Franck Morschhause
Source: ash.confex.comCategories: General Medicine News, Hematologists1Tweet-
📌#ASH23 [Top 10 agressive B-cell NHL abstracts] Abstract 893 - Pierre Sesques et al. @LysaLymphoma Glofitamab monotherapy in patients with B-Cell NHL after failing #CARTCell infusion (Bicar Phase II study). 👉https://t.co/9ixcAPHZma
-
-
Mashup Score: 5
Program: Oral and Poster Abstracts Type: Oral Session: 624. Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Advances in the Treatment of Hodgkin Lymphoma Hematology Disease Topics & Pathways: Research, Hodgkin lymphoma, clinical trials, Lymphomas, Clinical Research, Combination therapy, Diseases, Therapies, Lymphoid Malignancies 1 Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 2 Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta,
Source: ash.confex.comCategories: General Medicine News, Hematologists1Tweet-
2/5 📌#ASH23 [Top Hodgkin lymphoma abstracts] Abstract 610 by @SharonCastelli2 et al. Nivolumab-AVD compared to Brentuximab Vedotin-AVD in pediatric advanced stage classic Hodgkin #lymphoma (SWOG S1826 trial). 👉https://t.co/bzAeX4autR https://t.co/Xyd9h0bIiO
-
-
Mashup Score: 0Happy thus survivor? A systematic review and meta‐analysis on the association between cancer survival and positive states, emotions, and traits - 7 month(s) ago
Objectives Traditionally, the literature investigating patient-reported outcomes in relation to cancer survival focused on negative factors such as distress. Meta-analyses in this field have provide…
Source: onlinelibrary.wiley.comCategories: Hematologists1, Latest HeadlinesTweet-
In a meta-analysis, positive affect is associated with longer survival and lower mortality in patients with #cancer! Main predictors of survival are emotional/physical well-being, optimism and vitality. ➡️Promoting positive affect may be beneficial! https://t.co/vFHxzrp2vS
-
-
Mashup Score: 13Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial - 7 month(s) ago
Key Points. NRD is not inferior to traditional PD during neutropenia after HSCT.Multiple myeloma diagnosis, antibiotic prophylaxis, and absence of mucositis red
Source: ashpublications.orgCategories: Hematologists1, Latest HeadlinesTweet-
Nonrestrictive diet is not inferior to traditional protective diet during the neutropenic phase after HSCT (auto or allo). Hopefully, all centers will soon stop using restrictive diets, an unnecessary burden for patients’ quality of life. 👉https://t.co/chaLp2xAou #bmtsm https://t.co/lq5PJCyr9B
-
-
Mashup Score: 2Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options - 8 month(s) ago
See the latest #MultipleMyeloma live event from @PeerView #ASH23 #MedEd
Source: api.lrn.peerview.comCategories: Hematologists1, Latest HeadlinesTweet-
RT @Mohty_EBMT: Live event during #ASH23 #MedEd https://t.co/qJQpevKE2U @TheIACH @COMyCongress @ASH_hematology https://t.co/Is2813B1Zs
-
-
Mashup Score: 0Become a donor | WMDA - 8 month(s) ago
Join a community of over 41 million donorsSeveral types of life threatening blood cancer and a few other genetic disorders, like sickle cell disease, can be fully cured by a blood stem cell, marrow or cord blood transplantation if a suitable donor can be found. Although there are already many donors, there is still a need for more, because for 40% of patients we are unable to find a matched…
Source: WMDACategories: Hematologists1, Latest HeadlinesTweet-
How to become a donor? It’s relatively easy! Find out which organisation is active in your country and whether you are eligible to be a donor ! 👉https://t.co/u6ZcbDJyQc Cc @MarrowDonorDay @WMDA_office @AnthonyNolan #WMDD #WMDD23 https://t.co/uuwEIx2wlJ
-
-
Mashup Score: 0Dernières informations avant de vous engager | Don de moelle osseuse - 8 month(s) ago
Laissez-nous votre email afin d’être tenu(e) au courant des actualités sur le don de la moelle osseuse (chiffres clés, évènements, témoignages…) Les informations recueillies à partir de ce formulaire font l’objet d’un traitement informatique par l’Agence de la biomédecine (1 avenue du Stade de France, 93212 SAINT DENIS LA PLAINE Cedex, n° SIRET 180 092 587 00013) en tant que responsable…
Source: www.dondemoelleosseuse.frCategories: Hematologists1, Latest HeadlinesTweet-
Comment devenir donneur de moelle osseuse ? C’est très simple. Voici toutes les infos 👉 https://t.co/7YCvUNyhjL Nous avons #besoindechacun. La diversité des profils recherchés est un enjeu décisif. #dondemoelleosseuse #jmdmo #sauverdesvies https://t.co/JkDOiTOsa8
-
-
Mashup Score: 12Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial - 8 month(s) ago
Nature Medicine – Second-line treatment with axicabtagene ciloleucel, a CD19-targeting CAR-T cell therapy, resulted in high response rates and durable remissions in patients with high-risk large B…
Source: www.nature.comCategories: Hematologists1, Latest HeadlinesTweet-
✨New in @NatureMedicine! 2nd line treatment with axi-cel #CARTcells resulted in high response rates and durable remissions in patients with transplant-ineligible large B-cell lymphoma. Kudos to @HouotRoch, @BachyEmmanuel, and the @LysaLymphoma team!👏 https://t.co/Gaw6N6Z4Yk
-
📌#ASH23 [Top 10 agressive B-cell NHL abstracts] Abstract 103 - Michael Roderick Cook et al. Real-world evidence in the US of the impact of bridging therapy prior to axi-cel for R/R LBCL. #CARTcell #TcellRx 👉https://t.co/F9kbiOxKpo #lymsm https://t.co/aTBvUDx0fQ